MedTrace Logo

Skittles(TM) Effective for Treating Hypoglycemia in Children With Type 1 Diabetes

NCT00706693 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2008-07-09

No results posted yet for this study

Summary

The purpose of this study is to determine the most effective treatment option for managing naturally occurring hypoglycemia in children with type 1 diabetes.

Hypotheses:

1. Sucrose and Fructose are equally effective as glucose in the treatment of spontaneous hypoglycemia in children with type 1 diabetes.
2. Children and teens will use a variety of treatment practices for the management of hypoglycemia.
3. Children and teens will prefer the mode of treatment that was most effective in treating hypoglycemia.

Conditions

Interventions

DIETARY_SUPPLEMENT

Ingestion of BD glucose tablets (TM)

Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.

DIETARY_SUPPLEMENT

Ingestion of Skittles (TM)

Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.

DIETARY_SUPPLEMENT

Ingestion of Fruit to Go (TM)

Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.

Sponsors & Collaborators

  • Canadian Diabetes Association

    collaborator OTHER

  • LifeScan Canada

    collaborator UNKNOWN

  • Becton, Dickinson and Company

    collaborator INDUSTRY

  • University of Calgary

    lead OTHER

Principal Investigators

  • Allison Husband, RN, MN, CDE · Alberta Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2006-09-30
Completion
2006-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00706693 on ClinicalTrials.gov